Brief: AnaptysBio Q3 Net Income USD -32.851 Million
05/11/2024 21:15
Nov 05 (Reuters) - AnaptysBio Q3 operating expenses USD 52.774 million. * Q3 income from operations USD -22.757 million * Q3 collaboration revenue USD 30.017 million
Recent news on AnaptysBio
See all newsFirst Tracks Biotherapeutics up after $200 mln equity raise
US RESEARCH ROUNDUP-Alnylam Pharmaceuticals, Carvana, MongoDB
US RESEARCH ROUNDUP- Allstate, Autozone, Vertex Pharmaceuticals
Brief: Anaptys Announces Second Quarter And Transitional Fiscal Year 2026 Financial Results And Provides Business Update
AnaptysBio Q2 collaboration revenue rises on higher Jemperli royalties